Abstracts tagged "Biomarkers"

Abstract Number: 1231 • ACR Convergence 2021
Consistent Impact of Autoantibody Enrichment Across All ACR Core Measures in Early Rheumatoid Arthritis Treated with Abatacept: Data from a Large Pooled Analysis of 4 Randomized Controlled Trials
Philip Conaghan¹, Sang Hee Park², Mirko Fillbrunn³, Karissa Lozenski², Vadim Khaychuk², Kaleb Michaud⁴, Elyse Swallow³, Henry Lane³, Ha Nguyen³ and Janet Pope⁵, ¹Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, ²Bristol Myers Squibb, Princeton, NJ, ³Analysis Group, Inc., Boston, MA, ⁴University of Nebraska Medical Center, Omaha, NE, ⁵University of Western Ontario, London, ON, Canada
Background/Purpose: Biomarkers play an important role in RA and can help guide treatment decisions. Previous studies have suggested differential treatment efficacy of abatacept (ABA) in…
Abstract Number: 1453 • ACR Convergence 2021
Lung Interleukin-33 Is Elevated in Rheumatoid Arthritis-Associated Lung Disease
Rohit Gaurav¹, Ted Mikuls¹, Geoffrey Thiele¹, Bryant England¹, Madison Wolfe¹, Kristina Bailey¹, Amy Nelson¹, Michael Duryee¹, Debra Romberger¹, Dana Ascherman² and Jill Poole¹, ¹University of Nebraska Medical Center, Omaha, NE, ²University of Pittsburgh, Pittsburgh, PA
Background/Purpose: The alarmin interleukin (IL)-33 is a member of the IL-1 cytokine family that is rapidly released from the nucleus of a variety of lung…
Abstract Number: 1789 • ACR Convergence 2021
Prediction of Psoriatic Arthritis in Patients with Psoriasis Using DNA Methylation Profiles
Omar Cruz Correa¹, Remy Pollock¹, Rohan Machhar² and Dafna Gladman³, ¹University Health Network, Toronto, ON, Canada, ²Krembil Research Institute, University Health Network, Toronto, ON, Canada, ³Schroeder Arthritis Institute, Krembil Research Institute, Toronto Western Hospital, Toronto, ON, Canada
Background/Purpose: Psoriatic arthritis (PsA) poses an immense clinical burden with significantly increased morbidity and mortality risk compared to psoriasis alone. PsA may develop in 30%…
Abstract Number: 0340 • ACR Convergence 2021
Urinary L-selectin Predicts Disease Activity and Histological Changes in Lupus Nephritis
Huihua Ding¹, Yiwei Shen¹, Min Dai¹, Chandra Mohan² and Nan Shen³, ¹Shanghai JiaoTong University School of Medicine, Shanghai, China (People's Republic), ²University of Houston, Houston, TX, ³Shanghai Jiang Tong University School of Medicine, Shanghai, China (People's Republic)
Background/Purpose: There remains unmet needs of non-invasive markers of disease activity, damage, prognosis, and treatment response in lupus nephritis patients. Here, we aim to validate…
Abstract Number: 0502 • ACR Convergence 2021
Global Transcriptomic Profiling Identifies Differential Gene Expression Signatures Between Inflammatory and Non-inflammatory Aortic Aneurysms
Benjamin Hur¹, Matthew Koster¹, Jin Sung Jang¹, Kenneth Warrington² and Jaeyun Sung¹, ¹Mayo Clinic, Rochester, MN, ²Mayo Clinic, Rochester, Minnesota
Background/Purpose: Non-infectious aortitis may be a manifestation of systemic large vessel vasculitis such as giant cell arteritis (GCA) or may be a form of single…
Abstract Number: 0980 • ACR Convergence 2021
Relationship Between Paraoxonase-1 Genotype, Activity, and Malignancies in Patients with RA Receiving Tofacitinib
Christina Charles-Schoeman¹, Craig Hyde², Shunjie Guan³, Neil Parikh¹, Jennifer Wang¹, Ani Shahbazian¹, Lori Stockert⁴ and John Andrews⁴, ¹Department of Medicine, University of California, Los Angeles, Los Angeles, CA, ²Pfizer Inc, Groton, CT, ³Pfizer Inc, Cambridge, MA, ⁴Pfizer Inc, Collegeville, PA
Background/Purpose: Paraoxonase-1 (PON1) is a high-density lipoprotein-associated enzyme with paraoxonase, lactonase, and arylesterase activities.1 PON1 gene polymorphisms at the Q192R allele (rs662) have been associated…
Abstract Number: 1240 • ACR Convergence 2021
Biomarker Driven Dissection of Inflammation Modulatory Effects of Upadacitinib versus Abatacept in Patients with Active Rheumatoid Arthritis Refractory to Biologic DMARDs
Fang Cai¹, Thierry Sornasse², Feng Hong³, Heidi Camp⁴, Koji Kato⁵ and Iain McInnes⁶, ¹AbbVie, Redwood City, CA, ²AbbVie Inc, Redwood City, CA, ³AbbVie, Worcester, MA, ⁴AbbVie Inc., North Chicago, IL, ⁵AbbVie Inc, Shinagawa- Ku, Japan, ⁶University of Glasgow, School of Medicine, Glasgow, Scotland, United Kingdom
Background/Purpose: In patients with active rheumatoid arthritis (RA) refractory to biologic DMARDs (bDMARD-IR), a phase 3, double-blind and active-controlled study (SELECT-CHOICE) demonstrated that upadacitinib (UPA)…
Abstract Number: 1475 • ACR Convergence 2021
Long Term Compressive Loading Modulates the Extracellular Matrix Response to Growth Factors in Bovine Cartilage Explants
Frederik Gillesberg¹, Amalie Engstrøm¹, Morten Karsdal², Anne-Christine Bay-Jensen³ and Christian S Thudium³, ¹University of Copenhagen, Herlev, Denmark, ²Nordic Bioscience, Herlev, ³Nordic Bioscience, Herlev, Denmark
Background/Purpose: Mechanical loading of cartilage is an essential part of the function and maintenance of the joint. Despite the apparent importance of continuous mechanical loading,…
Abstract Number: 1816 • ACR Convergence 2021
Treatment of Non-biologic-DMARD-IR PsA Patients with Upadacitinib or Adalimumab Results in the Modulation of Distinct Functional Pathways: Proteomics Analysis of a Phase 3 Study
Thierry Sornasse¹, Jaclyn Anderson², Koji Kato³, Apinya Lertratanakul⁴, Christopher Ritchlin⁵ and Iain McInnes⁶, ¹AbbVie Inc, Redwood City, CA, ²AbbVie Inc, Gurnee, IL, ³AbbVie Inc, Shinagawa- Ku, Japan, ⁴AbbVie Inc., North Chicago, IL, ⁵Division of Allergy, Immunology, and Rheumatology, School of Medicine and Dentistry, University of Rochester Medical Center, Rochester, NY, ⁶University of Glasgow, School of Medicine, Glasgow, Scotland, United Kingdom
Background/Purpose: Treatment of non-biologic-DMARD-IR (DMARD-IR) PsA patients with upadacitinib (UPA) at 15 mg QD, an oral JAK1 selective inhibitor, resulted in improvement in musculoskeletal symptoms,…
Abstract Number: 0342 • ACR Convergence 2021
RAIL Distinguishes Responder and Non-Responder in Pediatric Lupus Nephritis
Ellen Cody¹, Scott Wenderfer², Qing Ma¹, Angela Merritt¹, Prasad Devarajan¹ and Hermine Brunner¹, ¹Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ²Baylor College of Medicine, Houston, TX
Background/Purpose: Systemic Lupus Erythematosus (SLE) is a diagnostic and therapeutic challenge, particularly lupus nephritis (LN). We described a composite score, the Renal Activity Index for…
Abstract Number: 0532 • ACR Convergence 2021
Development of a Predictive Tool for the Rapid Progressive Knee Osteoarthritis Phenotype: Data from the Osteoarthritis Initiative
Alejandro Durán-Sotuela¹, Mercedes Fernández-Moreno¹, Maria Vázquez-Mosquera¹, Paula Ramos-Louro¹, Andrea Dalmao-Fernández¹, Sara Relaño¹, Victoria Suárez-Ulloa², Vanesa Balboa-Barreiro³, Natividad Oreiro¹, Jorge Vázquez-García¹, Francisco Blanco-García⁴ and Ignacio Rego-Pérez¹, ¹Servicio de Reumatología. Instituto de Investigación Biomédica de A Coruña (INIBIC). Complexo Hospitalario Universitario de A Coruña (CHUAC), Sergas. Universidade da Coruña (UDC). As Xubias, 15006. A Coruña, España, A Coruña, Spain, ²Plataforma de Bioinformática. Instituto de Investigación Biomédica de A Coruña (INIBIC). Complexo Hospitalario Universitario de A Coruña (CHUAC), Sergas. Universidade da Coruña (UDC). As Xubias, 15006, A Coruña, Spain, ³Unidad de apoyo a la Investigación. Instituto de Investigación Biomédica de A Coruña (INIBIC). Complexo Hospitalario Universitario de A Coruña (CHUAC), Sergas. Universidade da Coruña (UDC). As Xubias, 15006. A Coruña, España, A Coruña, Spain, ⁴Unidad de Proteómica. Grupo de Investigación de Reumatología (GIR). Instituto de Investigación Biomédica de A Coruña (INIBIC), Complexo Hospitalario Universitario de A Coruña (CHUAC), Sergas. Universidade da Coruña (UDC). C/ As Xubias de Arriba 84, 15006, A Coruña, España.Universidade da Coruña (UDC), Grupo de Investigación de Reumatología y Salud (GIR-S). Departamento de Fisioterapia, Medicina y Ciencias Biomédicas, Facultad de Fisioterapia, Campus de Oza, 15008, A Coruña, España., A Coruña, Spain
Background/Purpose: There is a pressing need of identifying patients suffering the rapid progressive phenotype of Osteoarthritis (RPOA) to implement prevention strategies and to include them…
Abstract Number: 0982 • ACR Convergence 2021
B Cells Repertoire Repartition Predicts Response to Methotrexate at 6 and 12 Months in Naïve RA: A Machine Learning Driven Approach
Aurelie Najm¹, Shrutii Sarda², Michelle Toro³, Loni Pickle³, Stephanie Ostresh³, Fraser Morton⁴, Geoffrey Lowman³, Andrew Felton⁵ and Carl Goodyear⁴, ¹Institute of Infection, Immunity and Inflammation, College of Medical Veterinary and Life Sciences, University of Glasgow, Glasgow, United Kingdom, ²Clinical Sequencing Division, Specialty Diagnostics Group, Thermo Fisher Scientific, South San Francisco-CA, United States, San Francisco, ³Clinical Sequencing Division, Specialty Diagnostics Group, Thermo Fisher Scientific, Carlsbad, CA, ⁴University of Glasgow, Glasgow, United Kingdom, ⁵VP, Platforms, Research & Applied, Specialty Diagnostics Group, South San Francisco, CA
Background/Purpose: The adaptive immune system plays a central role in Rheumatoid Arthritis (RA) pathogenesis. Moreover, the composition of the B cell repertoire and its perturbation…
Abstract Number: 1241 • ACR Convergence 2021
Comparison of the Effects of Upadacitinib Monotherapy with MTX on Protein Biomarkers in MTX-Naïve and MTX-Inadequate Responders in Patients with Active Rheumatoid Arthritis: Results from the SELECT-EARLY and SELECT‑MONOTHERAPY Phase 3 Studies
Thierry Sornasse¹, Heidi Camp², Fang Cai³, Justin Klaff² and Iain McInnes⁴, ¹AbbVie Inc, Redwood City, CA, ²AbbVie Inc., North Chicago, IL, ³AbbVie, Redwood City, CA, ⁴University of Glasgow, School of Medicine, Glasgow, Scotland, United Kingdom
Background/Purpose: In MTX-naïve patients (SELECT-EARLY/M13-545 Phase 3 study) UPA 15 mg QD monotherapy (UPA Mono) demonstrated significant and clinically meaningful improvements in RA signs and…
Abstract Number: 1477 • ACR Convergence 2021
Circulating MicroRNAs in Hand Osteoarthritis
Aneta Pekacova¹, Jiri Baloun¹, Olga Sleglova¹, Jiri Vencovsky¹, Karel Pavelka², Ladislav Senolt² and Olga Ruzickova¹, ¹Institute of Rheumatology, Prague, Czech Republic, ²Institute of Rheumatology, Department of Rheumatology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic
Background/Purpose: microRNAs (miRNAs) are small non-coding RNAs that can ignite the degradation of mRNAs or inhibit the protein translation and are therefore essential for several…
Abstract Number: 1837 • ACR Convergence 2021
KL-6, CXCL11 and CTGF Are Potential Biomarkers in Response to Treatment in CTD-ILD
Yu-Hsiang Chiu¹, Mareye Voortman¹, Eveline Delemarre¹, Stefan Nierkens¹, Pim de Jong¹, Firdaus Mohamed Hoesein¹, Jan Grutters², Jacob van Laar¹ and Julia Spierings³, ¹University Medical Centre Utrecht, Utrecht, Netherlands, ²St. Antonius Hospital, Nieuwegein, Netherlands, ³University Medical Center Utrecht, Utrecht, Netherlands
Background/Purpose: Connective tissue disease related interstitial lung disease (CTD-ILD) is common and an important cause of morbidity and mortality. We aimed to identify biomarkers in…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].